Company intelligence / Profile preview

Clinical Genomics Technologies

North Ryde, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Clinical Genomics develops and markets in vitro diagnostic assays and screening tests for early detection and monitoring of colorectal cancer and colorectal neoplasia; its lead products are commercial laboratory and kit-based tests that measure methylated DNA biomarkers in blood or stool for colorectal cancer screening and post‑treatment surveillance.[1][5][7][9]

Therapeutic areas: OncologyGastroenterology
Modalities: DeviceNon-pharmacological therapy
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Clinical Genomics Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clinical Genomics Technologies.

Explore the full profile